Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.48 |
| ▸ | PDE4A | P27815 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361758 | 0.79 | PDE5A (0.52) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL715016 | 0.73 | PDE5A (0.62) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL715015 | 0.73 | PDE5A (0.62) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2705471 | 0.73 | PDE5A (0.62) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7435158 | 0.71 | PDE5A (0.50) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2362657 | 0.69 | PDE5A (0.52) | PDE5APDE4APDE3B | |
| SCHEMBL2362857 | 0.68 | PDE4A (0.49) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12321567 | 0.67 | PDE5A (0.53) | PDE5APDE4APDE3B | |
| SCHEMBL2362342 | 0.66 | PDE4A (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2362351 | 0.66 | PDE5A (0.49) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358204-B1 | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. | INTRA CELLULAR THERAPIES INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150072965-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140148421-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8664207-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20110237561-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-09-29 | — | — | US | disclosed |
| EP-2358204-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010065148-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148421-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE5A 1584/4885PDE4A 989/4885PDE4B 828/4885 |
| US-20150072965-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE5A 1584/4885PDE4A 989/4885PDE4B 828/4885 |
| US-20110237561-A1 | ORGANIC COMPOUNDS | TPMT, TYMS, THPO | PDE5A 1584/4885PDE4A 989/4885PDE4B 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.